SCHEMBL2425691

SCHEMBL2425691

CC(C)(C)OC(=O)c1ccc(C(=O)O)c2[nH]ccc12

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KEAP1 Q14145 1/20 0.41
AURKA O14965 2/20 0.37
TPX2 Q9ULW0 2/20 0.37
PIM3 Q86V86 2/20 0.36
PIM1 P11309 1/20 0.36
BTK Q06187 2/20 0.34
NUDT1 P36639 1/20 0.34
HTT P42858 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
GABRA1 P14867 1/20 0.33
GABRG2 P18507 1/20 0.33
GABRB3 P28472 1/20 0.33
GABRA3 P34903 1/20 0.33
GABRA2 P47869 1/20 0.33
ALDH1A1 P00352 1/20 0.33
TSHR P16473 1/20 0.33
HSD17B10 Q99714 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
P2RX7 Q99572 1/20 0.32
CFB P00751 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2428082 0.87 BTK (0.48) BTK
SCHEMBL2428090 0.87 PIM3 (0.47) PIM3PIM1NUDT1HTTALDH1A1
SCHEMBL11660386 0.80 KEAP1 (0.55) KEAP1AURKATPX2PIM1BTK
SCHEMBL1415186 0.76 NR4A1 (0.44) GABRA1GABRG2GABRB3GABRA3GABRA2
SCHEMBL8562952 0.76 ALDH1A1 (0.38) KEAP1SMN1; SMN2GABRA1GABRG2GABRB3
SCHEMBL31210541 0.74 GOT1 (0.47) BTKSMN1; SMN2ALDH1A1
SCHEMBL27658621 0.74 DHPS (0.52) GABRA1GABRG2GABRB3GABRA3GABRA2
SCHEMBL7497434 0.74 PIM3 (0.55) PIM3PIM1NUDT1HTTALDH1A1
SCHEMBL2768819 0.74 KEAP1 (0.49) KEAP1AURKATPX2BTKHTT
SCHEMBL10608089 0.73 CYP1A2 (0.56) ALDH1A1TSHRHSD17B10TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101910168-B Tropane compounds EXELIXIS INC 2014-07-30 CN disclosed
US-8012956-B2 Tropane compounds EXELIXIS, INC. (US) 2011-09-06 US disclosed
CN-101910168-A Tropane compounds EXELIXIS INC 2010-12-08 CN disclosed
EP-2074120-B1 TROPANE COMPOUNDS EXELIXIS INC (US) 2010-03-03 EP disclosed
EP-2074120-A1 TROPANE COMPOUNDS Exelixis, Inc. (US) 2009-07-01 EP disclosed
US-20090163471-A1 Tropane compounds EXELIXIS, INC. 2009-06-25 US disclosed
WO-2009055077-A1 TROPANE COMPOUNDS EXELIXIS, INC. (US) 2009-04-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090163471-A1 Tropane compounds ADRA1B, ADRA2B, ADRB2 KEAP1 4080/4885AURKA 3571/4885TPX2 1396/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.